Cantor Fitzgerald initiated coverage of Novo Nordisk with an Overweight rating and $120 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- Compounded Wegovy Matters Sink Novo Nordisk (NYSE:NVO)
- Eli Lilly (NYSE:LLY) Pops Up after Beating Novo Nordisk in Weight Loss
- Lilly’s Mounjaro more effective than Ozempic for weight loss in study, CNBC says
- Novo Nordisk (NYSE:NVO) Falls as Large Investor Offloads Shares
- Novo Nordisk in talks about flexible pricing for Wegovy, FT reports